University of Zurich registers Phase 2 safusidenib trial in IDH1-mutant grade 3 glioma

This week's activity centers on a newly posted academic trial involving Nuvation Bio's safusidenib.

• A Phase 2 study titled "Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma" (NCT07832123) was first posted, sponsored by the University of Zurich with Nuvation Bio Inc. and University Hospital Zürich as collaborators. The study is not yet recruiting, with an estimated start of March 2027 and estimated primary completion in March 2029¹, and plans to enroll 20 participants who will all receive safusidenib at 250 mg BID until progression or unacceptable toxicity¹.
• The trial's primary outcome is progression-free survival at 12 months, measured by central review of MRI¹. The study describes safusidenib as a novel, oral, potent, brain penetrant inhibitor of mutant IDH1 that has shown high blood brain barrier penetration in preclinical and clinical studies with complete or partial responses observed¹.